Analyst Price Targets — NAMS
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 19, 2026 12:21 pm | — | Guggenheim | $45.00 | $35.76 | TheFly | NewAmsterdam Pharma price target raised to $45 from $41 at Guggenheim |
| January 21, 2026 11:35 am | — | RBC Capital | $47.00 | $32.41 | TheFly | NewAmsterdam Pharma price target raised to $47 from $44 at RBC Capital |
| January 6, 2026 9:33 am | Roanna Ruiz | Leerink Partners | $55.00 | $33.48 | StreetInsider | NewAmsterdam Pharma Co NV (NAMS) PT Raised to $55 at Leerink Partners |
| December 2, 2025 11:38 am | — | Goldman Sachs | $37.00 | $39.61 | TheFly | NewAmsterdam Pharma price target raised to $37 from $30 at Goldman Sachs |
| October 20, 2025 10:16 am | Joseph Pantginis | H.C. Wainwright | $52.00 | $36.40 | TheFly | NewAmsterdam Pharma assumed with a Buy at H.C. Wainwright |
| August 25, 2025 9:53 am | — | Wells Fargo | $45.00 | $24.70 | TheFly | NewAmsterdam Pharma initiated with an Overweight at Wells Fargo |
| March 3, 2025 1:48 pm | — | UBS | $41.00 | $20.27 | TheFly | NewAmsterdam Pharma price target raised to $41 from $35 at Guggenheim |
| December 30, 2024 11:11 am | Ed Arce | H.C. Wainwright | $48.00 | $25.60 | TheFly | NewAmsterdam Pharma initiated with a Buy at H.C. Wainwright |
| November 20, 2024 9:10 pm | Roanna Ruiz | Leerink Partners | $45.00 | $20.01 | StreetInsider | NewAmsterdam Pharma Co NV (NAMS) PT Raised to $45 at Leerink Partners |
| September 23, 2024 7:20 am | Yasmeen Rahimi | Piper Sandler | $37.00 | $15.95 | StreetInsider | Piper Sandler Reiterates Overweight Rating on NewAmsterdam Pharma Co NV (NAMS) |
Latest News for NAMS
NewAmsterdam Pharma Company N.V. (NASDAQ: NAMS - Get Free Report) CEO Michael Davidson sold 183,332 shares of the business's stock in a transaction that occurred on Thursday, February 26th. The shares were sold at an average price of $33.71, for a total value of $6,180,121.72. Following the transaction, the chief executive officer directly owned 174,144 shares
NewAmsterdam Pharma Company N.V. (NASDAQ: NAMS - Get Free Report) insider Johannes Jacob Piete Kastelein sold 45,481 shares of the business's stock in a transaction dated Friday, February 20th. The stock was sold at an average price of $35.31, for a total value of $1,605,934.11. Following the transaction, the insider directly owned 53,500 shares of the
NAARDEN, the Netherlands and MIAMI, Feb. 25, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or…
-- Approval decisions from EMA, UK and Switzerland regulators for obicetrapib and obicetrapib/ezetimibe fixed dose combination expected in 2H26 -- -- Phase 3 PREVAIL CVOT blinded event rate tracking in line with observed event rate in BROADWAY-- -- Topline data from RUBENS Phase 3 trial in patients with type 2 diabetes and metabolic syndrome expected by year-end 2026 -- -- $728.9 million in cash, cash…
NewAmsterdam Pharma (NASDAQ: NAMS) Chief Financial Officer Ian Somaiya said the company remains encouraged by early observations from its PREVAIL cardiovascular outcomes trial and reiterated plans to provide a mid-year update on study timelines during remarks at Guggenheim's 2026 Emerging Outlook Biotech Summit. PREVAIL timelines and event-rate observations Somaiya pointed back to comments the company made
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for NAMS.
U.S. House Trading
No House trades found for NAMS.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.